83 related articles for article (PubMed ID: 15863153)
1. Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer.
Horak P; Pils D; Roessler M; Tomek S; Elandt K; Zeillinger R; Zielinski C; Krainer M
Gynecol Oncol; 2005 May; 97(2):514-8. PubMed ID: 15863153
[TBL] [Abstract][Full Text] [Related]
2. Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms.
Fernàndez V; Jares P; Beà S; Salaverria I; Guino E; de Sanjosé S; Colomer D; Ott G; Montserrat E; Campo E
Haematologica; 2004 Nov; 89(11):1322-31. PubMed ID: 15531454
[TBL] [Abstract][Full Text] [Related]
3. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
[TBL] [Abstract][Full Text] [Related]
4. Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma.
Kim YT; Nam EJ; Yoon BS; Kim SW; Kim SH; Kim JH; Kim HK; Koo JS; Kim JW
Gynecol Oncol; 2005 Dec; 99(3):585-90. PubMed ID: 16084575
[TBL] [Abstract][Full Text] [Related]
5. Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancer.
Romano A; Lindsey PJ; Fischer DC; Delvoux B; Paulussen AD; Janssen RG; Kieback DG
Gynecol Oncol; 2006 May; 101(2):287-95. PubMed ID: 16360811
[TBL] [Abstract][Full Text] [Related]
6. Genetic variants in the death receptor 4 gene contribute to susceptibility to bladder cancer.
Wang M; Wang M; Cheng G; Zhang Z; Fu G; Zhang Z
Mutat Res; 2009 Feb; 661(1-2):85-92. PubMed ID: 19070628
[TBL] [Abstract][Full Text] [Related]
7. A single nucleotide polymorphism in the extracellular domain of TRAIL receptor DR4 at nucleotide 626 in gastric cancer patients in Japan.
Kuraoka K; Matsumura S; Sanada Y; Nakachi K; Imai K; Eguchi H; Matsusaki K; Oue N; Nakayama H; Yasui W
Oncol Rep; 2005 Aug; 14(2):465-70. PubMed ID: 16012731
[TBL] [Abstract][Full Text] [Related]
8. Germline NBS1 mutations in families with aggregation of Breast and/or ovarian cancer from north-east Poland.
Kanka C; Brozek I; Skalska B; Siemiatkowska A; Limon J
Anticancer Res; 2007; 27(4C):3015-8. PubMed ID: 17695489
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of the estrogen receptor-alpha gene in familial ovarian cancer.
Wu HJ; Sekine M; Kashima K; Hirai Y; Hatae M; Kobayashi I; Obata K; Enomoto T; Umesaki N; Ushijima K; Tanaka K;
J Obstet Gynaecol Res; 2005 Oct; 31(5):375-83. PubMed ID: 16176503
[TBL] [Abstract][Full Text] [Related]
10. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
11. An investigation of relationships between hypoxia-inducible factor-1 alpha gene polymorphisms and ovarian, cervical and endometrial cancers.
Konac E; Onen HI; Metindir J; Alp E; Biri AA; Ekmekci A
Cancer Detect Prev; 2007; 31(2):102-9. PubMed ID: 17418979
[TBL] [Abstract][Full Text] [Related]
12. Importance of xeroderma pigmentosum group D polymorphisms in susceptibility to ovarian cancer.
Costa S; Pinto D; Pereira D; Vasconcelos A; Afonso-Lopes C; Osório T; Lopes C; Medeiros R
Cancer Lett; 2007 Feb; 246(1-2):324-30. PubMed ID: 16677755
[TBL] [Abstract][Full Text] [Related]
13. Androgen, progesterone, and FSH receptor polymorphisms in ovarian cancer risk and outcome.
Ludwig AH; Murawska M; Panek G; Timorek A; Kupryjanczyk J
Endocr Relat Cancer; 2009 Sep; 16(3):1005-16. PubMed ID: 19458022
[TBL] [Abstract][Full Text] [Related]
14. Association of death receptor 4 haplotype 626C-683C with an increased breast cancer risk.
Frank B; Hemminki K; Shanmugam KS; Meindl A; Klaes R; Schmutzler RK; Wappenschmidt B; Untch M; Bugert P; Bartram CR; Burwinkel B
Carcinogenesis; 2005 Nov; 26(11):1975-7. PubMed ID: 15975957
[TBL] [Abstract][Full Text] [Related]
15. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
[TBL] [Abstract][Full Text] [Related]
16. Death receptor 4 variants and colorectal cancer risk.
Frank B; Shanmugam KS; Beckmann L; Hemminki K; Brenner H; Hoffmeister M; Chang-Claude J; Burwinkel B
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):2002-5. PubMed ID: 17035413
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk.
Lurie G; Wilkens LR; Thompson PJ; McDuffie KE; Carney ME; Terada KY; Goodman MT
Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2566-71. PubMed ID: 18086759
[TBL] [Abstract][Full Text] [Related]
18. Progesterone receptor (PROGINS) polymorphism and the risk of ovarian cancer.
Leite DB; Junqueira MG; de Carvalho CV; Massad-Costa AM; Gonçalves WJ; Nicolau SM; Lopes LA; Baracat EC; da Silva ID
Steroids; 2008 Jul; 73(6):676-80. PubMed ID: 18384825
[TBL] [Abstract][Full Text] [Related]
19. Somatic mitochondrial DNA mutations in primary and metastatic ovarian cancer.
Van Trappen PO; Cullup T; Troke R; Swann D; Shepherd JH; Jacobs IJ; Gayther SA; Mein CA
Gynecol Oncol; 2007 Jan; 104(1):129-33. PubMed ID: 16942794
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk.
Spillman MA; Schildkraut JM; Halabi S; Moorman P; Calingaert B; Bentley RC; Marks JR; Murphy S; Berchuck A
Gynecol Oncol; 2005 May; 97(2):543-9. PubMed ID: 15863158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
